Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 5 (May)

1. Penta-O-galloyl-beta-D-glucose induces S- and G(1)-cell cycle arrests in prostate cancer cells targeting DNA replication and cyclin D1.
   Carcinogenesis, 30(5): 818-23. [Abstract] [Full-text]
2. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.
   Carcinogenesis, 30(5): 769-76. [Abstract] [Full-text]
3. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer.
   Carcinogenesis, 30(5): 851-60. [Abstract] [Full-text]
4. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.
   Carcinogenesis, 30(5): 808-17. [Abstract] [Full-text]
5. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
   Carcinogenesis, 30(5): 841-50. [Abstract] [Full-text]
6. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
   Am J Epidemiol, 169(10): 1223-32. [Abstract] [Full-text]
7. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.
   Biochem Biophys Res Commun, 383(3): 280-5. [Abstract] [Full-text]
8. Breast and prostate cancer survival in Michigan: can geographic analyses assist in understanding racial disparities?
   Cancer, 115(10): 2212-21. [Abstract] [Full-text]
9. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
   Cancer, 115(10): 2104-10. [Abstract] [Full-text]
10. TMF/ARA160 downregulates proangiogenic genes and attenuates the progression of PC3 xenografts.
    Int J Cancer, 125(1): 43-53. [Abstract] [Full-text]
11. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
    Int J Cancer, 125(1): 1-8. [Abstract] [Full-text]
12. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.
    Oncogene, 28(18): 1993-2002. [Abstract] [Full-text]
13. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells.
    J Clin Endocrinol Metab, 94(5): 1761-7. [Abstract] [Full-text]
14. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Science, 324(5928): 787-90. [Abstract] [Full-text]
15. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 616-22. [Abstract] [Full-text]
16. Dose recalculation and the Dose-Guided Radiation Therapy (DGRT) process using megavoltage cone-beam CT.
    Int J Radiat Oncol Biol Phys, 74(2): 583-92. [Abstract] [Full-text]
17. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
    Cancer Sci, 100(5): 914-9. [Abstract] [Full-text]
18. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 404-11. [Abstract] [Full-text]
19. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers.
    Int J Radiat Oncol Biol Phys, 74(2): 388-91. [Abstract] [Full-text]
20. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 392-8. [Abstract] [Full-text]
21. Usefulness of diffusion-weighted imaging in the localization of prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 399-403. [Abstract] [Full-text]
22. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 377-82. [Abstract] [Full-text]
23. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 383-7. [Abstract] [Full-text]
24. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway.
    J Urol, 181(6): 2749-59. [Abstract] [Full-text]
25. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
    J Urol, 181(6): 2508-13; discussion 2513-4. [Abstract] [Full-text]
26. Pathological outcomes associated with the 17q prostate cancer risk variants.
    J Urol, 181(6): 2502-7. [Abstract] [Full-text]
27. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    J Urol, 181(6): 2520-4; discussion 2525. [Abstract] [Full-text]
28. Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
    J Urol, 181(6): 2515-8; discussion 2518-9. [Abstract] [Full-text]
29. Epigenetic mechanisms in the biology of prostate cancer.
    Semin Cancer Biol, 19(3): 172-80. [Abstract] [Full-text]
30. Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic prostate cancer.
    Biochem Biophys Res Commun, 383(4): 440-4. [Abstract] [Full-text]
31. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.
    Br J Cancer, 100(10): 1608-16. [Abstract] [Full-text]
32. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Br J Cancer, 100(10): 1603-7. [Abstract] [Full-text]
33. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.
    Proc Natl Acad Sci U S A, 106(19): 7933-8. [Abstract] [Full-text]
34. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.
    Oncogene, 28(19): 2051-63. [Abstract] [Full-text]
35. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer.
    Cancer Genet Cytogenet, 191(2): 73-7. [Abstract] [Full-text]
36. Probasin promoter-driven expression of ID1 is not sufficient for carcinogenesis in rodent prostate.
    J Histochem Cytochem, 57(6): 599-604. [Abstract] [Full-text]
37. Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.
    Eur J Med Chem, 44(8): 3175-87. [Abstract] [Full-text]
38. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
    J Clin Oncol, 27(15): 2450-6. [Abstract] [Full-text]
39. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    J Clin Oncol, 27(15): 2429-35. [Abstract] [Full-text]
40. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    J Clin Oncol, 27(15): 2436-42. [Abstract] [Full-text]
41. Combined MRI and MRS in prostate cancer: improvement of spectral quality by susceptibility matching.
    Rofo, 181(6): 531-5. [Abstract] [Full-text]
42. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables.
    Acta Radiol, 50(5): 562-9. [Abstract] [Full-text]
43. Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells.
    Cancer Lett, 280(1): 93-100. [Abstract] [Full-text]
44. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals.
    Oncogene, 28(20): 2074-86. [Abstract] [Full-text]
45. Imaging localized prostate cancer: current approaches and new developments.
    AJR Am J Roentgenol, 192(6): 1471-80. [Abstract] [Full-text]
46. Challenges in clinical prostate cancer: role of imaging.
    AJR Am J Roentgenol, 192(6): 1455-70. [Abstract] [Full-text]
47. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.
    Endocrinology, 150(6): 2674-82. [Abstract] [Full-text]
48. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.
    Am J Pathol, 174(6): 2051-60. [Abstract] [Full-text]
49. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer.
    Am J Pathol, 174(6): 2044-50. [Abstract] [Full-text]
50. In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT.
    Prostate, 69(9): 1001-16. [Abstract] [Full-text]
51. Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines.
    Prostate, 69(9): 982-90. [Abstract] [Full-text]
52. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.
    Prostate, 69(9): 1017-23. [Abstract] [Full-text]
53. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Prostate, 69(9): 909-16. [Abstract] [Full-text]
54. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Prostate, 69(9): 976-81. [Abstract] [Full-text]
55. Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase.
    Prostate, 69(9): 949-55. [Abstract] [Full-text]
56. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
    Prostate, 69(9): 961-75. [Abstract] [Full-text]
57. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts.
    Prostate, 69(9): 991-1000. [Abstract] [Full-text]
58. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
    Prostate, 69(9): 917-27. [Abstract] [Full-text]
59. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Prostate, 69(9): 938-48. [Abstract] [Full-text]
60. Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men.
    Prostate, 69(9): 956-60. [Abstract] [Full-text]
61. A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.
    Prostate, 69(9): 928-37. [Abstract] [Full-text]
62. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases.
    Eur J Surg Oncol, 35(7): 751-6. [Abstract] [Full-text]
63. Immunostaining of the androgen receptor and sequence analysis of its DNA-binding domain in canine prostate cancer.
    Vet J, 181(3): 256-60. [Abstract] [Full-text]
64. The chances of subsequent cancer detection in patients with a PSA > 20 ng/ml and an initial negative biopsy.
    ScientificWorldJournal, 9: 343-8. [Abstract] [Full-text]
65. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
    Cancer Immunol Immunother, 58(8): 1337-49. [Abstract] [Full-text]
66. Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor.
    Cancer Immunol Immunother, 58(8): 1319-28. [Abstract] [Full-text]
67. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment.
    JAMA, 301(20): 2141-51. [Abstract] [Full-text]
68. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection.
    Jpn J Clin Oncol, 39(6): 387-93. [Abstract] [Full-text]
69. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images.
    Jpn J Clin Oncol, 39(6): 394-8. [Abstract] [Full-text]
70. The Japanese guideline for prostate cancer screening.
    Jpn J Clin Oncol, 39(6): 339-51. [Abstract] [Full-text]
71. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
    Cancer Invest, 27(5): 549-60. [Abstract] [Full-text]

© 2004-2010 Prostate Cancer Research Today. All Rights Reserved.